Pharmacokinetics of mizoribine in adult living donor liver transplantation

M. Shinoda, M. Tanabe, S. Kawachi, Y. Ono, T. Hayakawa, O. Iketani, M. Kojima, O. Itano, H. Obara, M. Kitago, T. Hibi, K. Matsubara, N. Shimojima, Y. Fuchimoto, K. Hoshino, G. Wakabayashi, M. Shimazu, Y. Tanigawara, T. Kuroda, Y. MorikawaM. Kitajima, Y. Kitagawa

研究成果: Article査読

10 被引用数 (Scopus)

抄録

We investigated the pharmacokinetics of mizoribine in the acute phase after adult living donor liver transplantation (LDLT). Between February 2004 and October 2009, 16 recipients received immunosuppressive therapy that included mizoribine (100 to 200 mg/d) after undergoing LDLT. We determined the serum levels of mizoribine before (C0) and 3 (C3), 4 (C4), and 10 (C10) hours after administration on postoperative days 3, 7, and 21. We assessed area under the concentration time curve (AUC) (hour · μg/mL), normalized serum concentration (NSC) at C0 [concentration (μg/mL)/dose (mg/kg body weight)], and estimated glomerular filtration rate (eGFR). The mizoribine concentration showed increases at C3 and C4 followed by a decrease at C10 on all days. AUC was 4.3, 5.9, and 8.3 in the 200-mg/d dose group on days 3, 7, and 21, respectively. NSC at C0 increased for 3 weeks after LDLT. There was a significant correlation between the NSC at C0 and eGFR on day 21, but not on days 3 and 7. There were no correlations between the NSC at C0 and either aspartate aminotransferase, total bilirubin, albumin, trough cyclosporine, or trough tacrolimus on any day. The pharmacokinetics of mizoribine in the acute phase after LDLT seems to be affected by postoperative day and renal function.

本文言語English
ページ(範囲)1329-1335
ページ数7
ジャーナルTransplantation Proceedings
44
5
DOI
出版ステータスPublished - 2012 6

ASJC Scopus subject areas

  • 外科
  • 移植

フィンガープリント

「Pharmacokinetics of mizoribine in adult living donor liver transplantation」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル